Recently, the first product from the strategic collaboration between SoliPharma and Shanghai Pharmaceuticals Holding Sales Co., Ltd. (02607,HK; 601607, SH; hereinafter referred to as “SPH Sales”), Adapalene 0.1% Gel, has been officially approved for market launch by the National Medical Products Administration (NMPA Approval No. H20255217). This approval marks a significant breakthrough in the partnership and provides patients in the field of skin health with a new treatment option.
As the first product of this strategic partnership, the launch of Adapalene 0.1% Gel demonstrates the powerful synergy achieved through complementary strengths and collaborative advancement. Leveraging SoliPharma 's leading R&D capabilities and product innovation alongside SPH Sales’ robust commercial operations, this partnership accelerates clinical access to high-quality medications, jointly fulfilling their mission to “Safeguard Skin Health through Precision-Driven Delivery Technologies.
Adapalene 0.1% gel is a third-generation topical retinoid classified as a Category B National Medical Insurance drug and Category A OTC medication. It is primarily indicated for treating mild to moderate acne (including comedones, papules, and pustules), serving as the first-line monotherapy for mild acne globally and the preferred combination therapy and maintenance treatment for moderate acne. It improves acne through mechanisms including regulating skin cell differentiation, dissolving microcomedones, and suppressing inflammatory responses, offering both preventive and restorative effects. Consistent, long-term use is required.
This approved Adapalene 0.1% Gel is the second generic product in China to pass the national consistency evaluation, demonstrating equivalent quality and efficacy to the originator drug “Differin®”. Leveraging SoliPharma 's deep expertise in topical & transdermal delivery technology and SPH Sales ' extensive distribution network, this product offers acne patients a reliable alternative with equivalent quality to the innovator drug.
The approval of adapalene gel marks a significant milestone in SoliPharma’s “Focus on Skin Health” strategy. Moving forward, we will leverage this product as a starting point to deepen our strategic collaboration with SPH Sales, accelerating the advancement of our innovative pipeline in acne, atopic dermatitis, and hair health. This will enable more patients to benefit from the therapeutic breakthroughs delivered by precision topical & transdermal delivery technology. We remain committed to deepening our expertise in skin health, driving innovation through dual engines of technological advancement and industrial synergy. Our goal is to provide patients with superior, more accessible solutions, helping them achieve their aspirations for healthy skin.
